With respect to clinicopathological characteristics, our analysis revealed a significant association between median 5 year survival rate with late stage of breast cancer at diagnosis, negative HER2/neu receptor status and presence of metastasis (p<0.05). Here, ERBB2 is linked to breast cancer.